Legend Biotech Corporation Market Research Report

Background

Overview

Legend Biotech Corporation is a global clinical-stage biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. Established in 2014, the company operates across the United States, China, and Europe, with its global headquarters located in Somerset, New Jersey.

Mission and Vision

The company's mission is to extend and improve patients' lives by developing innovative cell therapies, with a focus on oncology and other intractable diseases. Its vision is to become the global leader in cell and gene therapy by creating transformative therapies that change treatment paradigms.

Primary Area of Focus

Legend Biotech's primary focus is on cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapies, targeting various cancers, including multiple myeloma, non-Hodgkin lymphoma, and solid tumors.

Industry Significance

As a pioneer in the CAR-T cell therapy revolution, Legend Biotech has made significant contributions to cancer care, offering innovative treatments for patients with relapsed or refractory multiple myeloma. Its collaboration with Janssen Biotech has been instrumental in advancing CAR-T therapies globally.

Key Strategic Focus

Core Objectives

• Develop and commercialize innovative cell therapies for oncology and other indications.

• Expand global manufacturing capacity to meet increasing patient demand.

• Strengthen strategic collaborations to enhance research and development capabilities.

Specific Areas of Specialization

• CAR-T cell therapies targeting B-cell maturation antigen (BCMA) for multiple myeloma.

• Development of allogeneic gamma delta CAR-T and CAR-NK cell therapies.

• Exploration of cell therapies for solid tumors, including non-Hodgkin lymphoma and other cancers.

Key Technologies Utilized

• Chimeric Antigen Receptor (CAR) T-cell technology.

• Allogeneic cell therapy platforms, including gamma delta T-cells and natural killer (NK) cells.

• Advanced manufacturing processes for cell therapy production.

Primary Markets Targeted

• United States

• Europe

• China

• Asia Pacific region

Financials and Funding

Funding History

Legend Biotech went public in 2020 through an initial public offering (IPO) on the NASDAQ Global Select Market, raising $424 million in gross proceeds.

Recent Funding Rounds

As of the latest available data, the company has not disclosed additional funding rounds post-IPO.

Notable Investors

The IPO attracted a diverse group of institutional and individual investors, though specific investor details are not publicly disclosed.

Utilization of Capital

Proceeds from the IPO have been allocated to:

• Advancing clinical development of lead product candidates.

• Expanding manufacturing capabilities.

• Strengthening strategic partnerships.

Pipeline Development

Key Pipeline Candidates

• LCAR-B38M (Ciltacabtagene Autoleucel): A CAR-T therapy targeting BCMA for relapsed or refractory multiple myeloma.

• LB1908: An allogeneic gamma delta CAR-T therapy targeting BCMA for multiple myeloma.

• LB2102: A CAR-T therapy targeting delta-like ligand protein 3 (DLL3) for solid tumors.

Stages of Clinical Trials

• LCAR-B38M: Approved by the U.S. FDA in February 2022 and received conditional marketing approval from the European Medicines Agency in May 2022.

• LB1908: Undergoing investigator-initiated Phase 1 clinical trials in China.

• LB2102: In early-stage development, with plans for clinical trials targeting solid tumors.

Target Conditions

• Multiple myeloma

• Non-Hodgkin lymphoma

• Solid tumors, including small cell lung cancer and large cell neuroendocrine carcinoma

Anticipated Milestones

• Expansion of clinical trials for LB1908 and LB2102.

• Regulatory submissions and approvals for LB2102.

• Commercial launch of LB1908 in China.

Technological Platform and Innovation

Proprietary Technologies

• CAR-T Cell Therapy: Utilizing patient-derived T-cells engineered to target specific cancer antigens.

• Allogeneic Cell Therapies: Developing off-the-shelf therapies using donor-derived cells.

Significant Scientific Methods

• Gene Editing: Employing CRISPR and other gene-editing technologies to enhance T-cell functionality.

• Manufacturing Processes: Implementing closed-system bioreactors and automated cell processing to improve scalability and consistency.

Leadership Team

Key Executives

• Ying Huang: Chief Executive Officer and Director.

• Lori MacOmber: Chief Financial Officer.

• Guowei Fang: Chief Scientific Officer and Head of Business Development.

• Mythili Koneru: Chief Medical Officer.

Professional Backgrounds

• Ying Huang: Extensive experience in biopharmaceutical leadership, previously serving in senior roles at leading pharmaceutical companies.

• Lori MacOmber: Background in financial management within the biotechnology sector.

• Guowei Fang: Expertise in immunology and cell therapy development, with a history of successful partnerships.

• Mythili Koneru: Clinical development experience, particularly in oncology and cell therapies.

Key Contributions

• Ying Huang: Led the company's strategic direction and growth initiatives.

• Lori MacOmber: Managed financial operations and investor relations.

• Guowei Fang: Oversaw scientific research and business development efforts.

• Mythili Koneru: Directed clinical development programs and regulatory affairs.

Leadership Changes

Recent Appointments

• Carlos Santos: Appointed Chief Financial Officer in August 2025.

Competitor Profile

Market Insights and Dynamics

The cell therapy market, particularly CAR-T therapies, is experiencing rapid growth, driven by advancements in immuno-oncology and increasing approvals for various cancers. The global market for CAR-T therapies is projected to expand significantly, with multiple myeloma being a key focus area.

Competitor Analysis

• Bristol Myers Squibb (BMY): Markets Abecma® (idecabtagene vicleucel), a BCMA-targeted CAR-T therapy for multiple myeloma.

• Gilead Sciences (GILD): Offers Yescarta® and Tecartus®, CAR-T therapies for various cancers.

• Novartis (NVS): Provides Kymriah®, a CAR-T therapy for certain leukemias.

Strategic Collaborations and Partnerships

• Janssen Biotech, Inc.: Collaboration for the development and commercialization of ciltacabtagene autoleucel.

• Novartis Pharma AG: License agreement for the development of CAR-T therapies targeting delta-like ligand protein 3 (DLL3).

Operational Insights

Legend Biotech's strategic collaborations enhance its research and development capabilities, while its global manufacturing infrastructure supports the scalability of its cell therapies. The company's focus on innovative cell therapy platforms positions it competitively in the oncology treatment landscape.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Expansion of Manufacturing Capacity: Increase production capabilities to meet global demand for CAR-T therapies.

• Pipeline Diversification: Advance therapies targeting solid tumors and other indications.

• Regulatory Approvals: Obtain approvals in additional markets to broaden patient access.

Future Business Directions

Legend Biotech aims to solidify its position as a leader in cell and gene therapy by expanding its product portfolio, enhancing manufacturing capabilities, and strengthening strategic partnerships.